Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 6: NNC0487-0111 in Overweight/Obesity and Knee Osteoarthritis
NCT07509307Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- Peptides, Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and osteoarthritis (OA) comparing NNC0487-0111 with Placebo (2 arms). Primary endpoints: Relative change in body weight at 80 weeks and Change in Western Ontario and McMaster Universities Osteoarthritis Index Numerical Rating Scale (NRS) 3.1 (24-hour) (WOMAC) pain score at 80 weeks. Started Apr 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
obesityOverweightosteoarthritis (OA)
Beyond the preview
Go deeper on NCT07509307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509307.